BetterLife Pharma (BETRF) Accumulated Expenses (2016 - 2026)

BetterLife Pharma's Accumulated Expenses history runs 11 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 10.09% year-over-year to $2.8 million; the TTM figure through Jan 2026 stood at $2.8 million (down 10.09% YoY), while the FY2026 annual figure was $2.8 million, down 10.09% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.8 million, down from $3.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.0 million in Q1 2023, with the low at $2.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $3.2 million (2025), against an average of $3.3 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses decreased 24.58% in 2022, then surged 52.67% in 2023.
• BetterLife Pharma's Accumulated Expenses stood at $2.6 million in 2022, then soared by 52.67% to $4.0 million in 2023, then dropped by 8.65% to $3.7 million in 2024, then retreated by 13.98% to $3.2 million in 2025, then retreated by 10.09% to $2.8 million in 2026.
• Business Quant data shows BETRF's Accumulated Expenses at $2.8 million in Q1 2026, $3.2 million in Q1 2025, and $3.7 million in Q1 2024.